Medical Writing Training Update

My colleagues on the AMWA listserv have been gracious enough to bring to my attention additional medical writing and biomedical communication training programs.  Natalie R. aka "healthypen" , a freelance medical writer in MA, recently received information from the University of Chicago about their newly created medical writing and editing certificate program . I also heard from the Head Writer Administrator at the Medical Writing Forum who also runs the Medical Writing Blog about other programs at Northeastern University, TuftsCarnegie Mellon and University of Houston-Downtown.   Check them out. I am sure that there are others that I failed to mention.  I would gladly post other medical writing training programs if you want to send them to me.

Until next time.....

Good Luck and Good Job Hunting!!!!!!!!!

Merck Jobs Update

The New York Times reported today that revenues are up at Merck but fourth quarter profits plunged 58% as the company took charges for restructuring, acquisition and legal resources related to the withdrawal of Vioxx. Charges for severance packages, site closings and other costs totaled $222 million for the fourth quarter. Merck eliminated 900 jobs in the fourth quarter and has cut 4,800 out of the 7,000 set to be eliminated by the end of 2008. I suspect that Merck, like many other big pharma companies that are on the ropes, will not be aggressively hiring  folks for a while. Simply put, the job market in NJ is looking mighty grim.

The pharma industry is consolidating which means that it is time to start thinking biotech, medical devices and business school.

Until next time.....



Good Luck and Good Job Hunting!!!!!!!!

Bristol-Myers Merger Likely to Cost Jobs

My local paper, the Trenton Times, reported today that the impending merger with the French drug maker Sanofi-Aventis will cost jobs in Mercer County, New Jersey.  BMS, headquartered in Lawrenceville NJ, employs 7,600 people, making it the third largest employer in Mercer County . The loss of jobs is likely after the merger because Sanofi-Aventis has a history of laying off employees after acquisitions and mergers. For example, after Sanofi-Synethelabo bought Aventis in 2004, the merged company laid off 700 workers in its New Jersey offices. Although neither BMS nor Sanofi-Aventis would confirm reports of merger talks, BMS has made several moves in recent months to indicate that it is up for sale.  In September 2006, Bristol-Myers officials confirmed for the first time that they would consider selling the company.  Earlier this month, the company sold three of its offices (located on prime real estate) in West Windsor and Plainsboro New Jersey. Finally, the New York Times reported today that BMS recently announced agreements with several top managers that "would allow them to walk away with significant compensation in the event of demotions, transfers or cuts in pay".

As consolidation continues in the pharmaceutical industy, jobs will be harder to find. It may be time for  those of you considering industrial careers to begin to explore alternate career options.

Until next time.........

Good Luck and Good Job Hunting!!!

BMS For Sale

Rumors are flying that Bristol Myers Squibb  (BMS) may be purchased or merged with European pharmaceutical giant Sanofi-Aventis. BMS and Sanofi have marketing agreements to sell the anti-clotting agent Plavix and the blood pressure treatment Avapro. The news has pushed BMS stock to a nearly three year high. Sources say that the merger could be announced within the next few weeks. BMS is still reeling from the Erbitux debacle of several years ago and the recent launch of a generic version of Plavix which flooded the market until a judge ordered generic manufacturer Apotex to stop distributing its version of Plavix.

This may be good news for BMS shareholders but bad news for BMS employees who will likely be right-sized if the merger is approved and takes place.

Stayed tuned for updates.

Until next time.....

Good Luck and Good Job Hunting!!!!!!

FDA Jobs?

In the January 2007 issue of Drug Discovery & Development, Ted Agres authored an informative article called "FDA's Sweeping Changes" that outlined reforms that are slated to occur at the agency. One of these is an amendment to the Prescription Drug User Fee Act (PDUFA; which is up for renewal) to increase user fees for regulatory reviews. For those of you who are not familiar with PDUFA, it was passed in 1992 and it authorized FDA to collect fees from industry to hire additional staff to meet faster approval goals for Investigational New Drug (IND), New Drug (NDA) and Biological License Applications (BLA). Under PDUFA, user fees have grown from $9 million or 7% of FDA's drug review costs in FY1993 to ca. $ $280 million or more than 59% in FY 2007 which began on Oct. 1, 2007.   Continue Reading...

Pharmaceutical and Biopharmaceutical Sales: A Career Option?

Most scientists have an inherent dislike and distrust of anything to do with marketing, advertising and sales. A good friend of mine (another Ph.D.) and I frequently joke about how the “less gifted and talented “students always migrated to careers in business as compared with we scientists. The mere mention of the word “sales” conjures up images of a smiling, glad-handing, salesman trying to sell cars at deceptively high prices. Like it or not, salespeople live or die simply on the amount of product they sell on a quarterly basis. That said, in today’s marketplace, it is easier to find a job in sales as compared with R&D.

Although there are similarities between traditional salespersons and pharmaceutical /biopharmaceutical sales representatives, i.e. they both have to sell as much as they can, the differences between these two types of salespeople are greater than you may think. First, unlike typical salespeople (where “on the fly”, high pressure, canned sales pitches are the norm), a pharmaceutical or biopharmaceutical sales rep must know his/her product(s) ‘backward and forward”. This is absolutely essential when a rep tries to convince a physician to buy his/her company’s product(s) as compared with competing brands. Price is always a consideration but safety and efficacy are much more important than price when selling drugs. Physicians are notoriously price insensitive–they typically treat their patients with drugs that they have experience with and have confidence in regardless of cost. Consequently, a well informed, scientifically-minded sales rep ought to be able to sell more product(s) to physicians as compared with one who is not. Second, “becoming informed” requires an enormous amount of education and training. The sales training offered by biopharmaceutical and pharmaceutical companies to their reps is intense and the competition to secure sales jobs is fierce. In the old days, the ideal sales reps were individuals with business backgrounds who had “some understanding” of scientific concepts. In stark contrast, today’s reps are typically undergraduate or graduate science Continue Reading...

Update on Pfizer Job Cuts

NEW YORK (Reuters) - Pfizer Inc.  on Monday said it plans to cut 7,800 more jobs, including more than 20 percent of its European sales force, in an effort to save up to an additional $1 billion by the end of 2008.

I guess it could have been worse......Stay tuned for more.

Good Luck and Good Job Hunting!!!!!!!!!!!!

Medical Writing and Medical Communications Training

Over the past few days, I received several inquiries regarding training for individuals interested in pursuing careers in medical writing and medical communications. The good news is that both of these fields are exploding and there simply are not enough qualified candidates to fill all of the positions that are open. The bad news is that there is very little formal training or instruction to prepare folks for jobs in these fields.

A few years ago, the University of the Sciences in Philadelphia started a M.S. degree and certificate program in medical writing. Also, James Madison University in Virginia created Continue Reading...

New Job Cuts at Pfizer?

The new CEO at Pfizer is contemplating new job cuts that may affect thousands of employees.  Also, sources close to the situation indicated that Pfizer will overhaul its drug discovery and development program so that the company can more efficiently discover and develop new products. These changes were not unexpected after the former CEO Hank McKinell ran the company into the ground and was rewarded with a severance package of over $200 million. Late last year Pfizer laid off hundreds of its sales representative to consolidate its sales force and cut costs. For you business minded folks out there, Pfizer is a case study in a company that expanded too quickly without a strategic vison or plan.  As I have noted previously, "bigger is not always better" in some situations.

Until next time....

Good Luck and Good Job Hunting!!!!!!!!!!!

Bioscience Companies: The Good, The Bad and The Ugly

Douglas Eisenhardt over at the Bostonworks.com 's JobBlog alerted me today that Fortune magazine published its annual 100 Best Companies To Work For List. A quick perusal of the list revealed that only 8 bioscience, pharmaceutical and healthcare-related companies made the list in 2007.

Three biotechnology companies that broke the top 100 included: Genentech (2), based in South Francisco, CA; Amgen (40), the largest biotechnology company in the world located in Thousand Oaks, CA; and Boston-based Genzyme (43). Pharmaceutical notables include Alcon (65) in the Lone Star State and Delaware-based Astra Zeneca (71).

Two healthcare consulting firms, Boston Consulting Group (8) and Booz Allen Hamilton (63), also made the cut. Finally, a single medical device company, Minnesota-based Medtronics, was also included. It is not a surprise that Genentech was ranked so high. Word on the street indicates that Genentech, the second largest biotechnology company in the world, still retains a very academic feel to it and treats its employees really well. Amgen, on the other hand, has lost its collegial atmosphere and, according to industry buzz, is run more like a pharmaceutical company than a biotechnology company. That said, Amgen did make the 100 Best List, so they are doing something right after all. Genzyme is one of the older biotechnology companies around and has a great reputation in the Boston area for treating its employees well.




Continue Reading...

R&D Jobs?

I was visiting a friend of mine over the holidays who works for Merck and she told me that 2006 was a busy year for the company.   She went on to tell me that she hired three new Ph.D. scientists into her group in the hypertension/cardiovascular therapeutic area.   I was very surprised to hear this and asked if the trend will continue in 2007.  Of course, she cannot predict the future, but she indicated that 2007 may be a better year than 2006.  I guess if  Merck continues to win its Vioxx lawsuits, hiring will continue at the company.   Other companies like Novartis are also expanding and are on a hiring spree.

The same is not true at Pfizer which is rapidly downsizing and laying off employees due to unrestrained and poorly managed growth in the late 1990s and early 2000s.  It still amazes me that the former CEO of Pfizer received a compensation package of approximately $200 million after driving the company's stock price into the basement.  Bristol Myers Squibb is also in a precarious situation due to the poor leadership of its ex-CEO (who was fired about 3 monthws ago).  Conventional wisdom suggests that BMS is looking for a suitor to buy the company.

So, after all is said and done, there may just be R&D jobs at pharmaceutical and biotechnology companies in 2007.   That said, keep on slogging.....

Until next time..........

Good Luck and Good Job Hunting!!!!!!!!